首頁 > 市場調查報告書 > 醫療設備

體外診斷癌症

市場調查報告書

商品編碼

1542917

全球循環腫瘤細胞 (CTC) 市場 - 2024-2031

Global Circulating Tumor Cells (CTC) Market - 2024-2031

出版日期: 2024年08月26日 | 出版商:

DataM Intelligence | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

循環腫瘤細胞市場規模

全球循環腫瘤細胞市場在2023年達到118億美元，預計到2031年將達到266.1億美元，在2024-2031年預測期間複合年成長率為11.1%。

循環腫瘤細胞（CTC）是從原發腫瘤脫落並進入周邊血液循環系統並導致轉移的腫瘤細胞。從臨床樣本中靈敏檢測 CTC 可作為透過液體活體組織切片進行癌症診斷和預後的有效工具。

目前的CTC檢測技術主要依賴生物標記介導的平台，包括磁珠、微流控晶片或尺寸敏感的微濾，這些平台可能會因腫瘤異質性而降低檢測靈敏度。最近開發了一種更靈敏、不依賴生物標記的 CTC 分離技術，該技術使用表面帶電的超順磁性奈米探針，能夠從 1 mL 臨床血液中捕獲不同的 EMT 亞群 CTC。

循環腫瘤細胞市場的促進因素與限制

癌症病例數不斷增加

癌症病例數的增加是預測期內幫助市場成長的重要關鍵因素之一。例如，根據國家衛生統計中心的數據。 2023 年，美國預計將出現 1,958,310 例新癌症病例和 609,820 例癌症死亡。前列腺癌的發生率在經歷了二十年的下降之後，從 2014 年到 2019 年每年增加 3%，意味著新增病例增加了 99,000 例；然而，除此之外，男性的發生率趨勢比女性更為有利。

隨著癌症盛行率的上升，對有效的癌症診斷和監測工具以及基於 CTC 的檢測和技術的需求不斷成長。這為市場上的公司開發創新產品和解決方案提供了重要機會，以實現 CTC 的檢測、計數和分子表徵。

此外，人們對液體活體組織切片方法日益成長的興趣進一步推動了對基於 CTC 的技術的需求，因為它們提供了一種即時監測癌症患者的非侵入性方法。

此外，循環腫瘤細胞市場也受到各種其他因素的推動，例如CTC檢測技術的進步、對快速癌症診斷的需求不斷增加、標靶治療的開發等也將有助於市場在預測期內成長。

市場動態：

克制

預測期內阻礙市場成長的各種因素包括嚴格的監管架構、CTC檢測的技術困難、成本控制措施、缺乏對先進CTC技術的了解以及產品上市核准的耗時要求。

循環腫瘤細胞細分市場分析

全球循環腫瘤細胞市場根據產品類型、技術、應用、樣本、最終用戶和地區進行細分。

從產品類型細分來看，器械細分市場約佔循環腫瘤細胞市場佔有率的43.5%

該產品類型細分市場的設備約佔 43.5%，預計在預測期內將佔據主導地位。該部門專注於開發和利用專為 CTC 相關應用設計的設備。為了提高技術能力並促進大規模生產，市場上出現了製造玻璃微晶片，可以解決挑戰並提高整體效率。

例如，2020 年 6 月，SCIENION AG 和 RareCyte Inc. 表示，cellenONE 被證明是在腫瘤學應用中精確單細胞分配少量模型循環腫瘤細胞 (CTC) 的最合適設備。 RareCyte 使用 SCIENIONO 法國子公司 Cellenion 的多功能技術，將預定數量的目標 CTC 精確且可重複地添加到血液樣本中。

循環腫瘤細胞市場地域佔有率

2022年北美約佔38.4%的市佔率

據估計，在整個預測期內，北美將佔據約38.4% 的總市場佔有率，原因是該地區癌症患病率不斷上升，加上診斷技術的進步以及醫療保健專業人員意識的提高，促進了癌症的蓬勃發展。此外，強大的醫療基礎設施，加上在研發方面的大量投資，為創新的 CTC 檢測和分析技術鋪平了道路。

例如，根據美國癌症協會2022年的估計，2022年該國將診斷出約236,740例新發肺癌病例。將報告腎癌。癌症的高負擔預計將增加對 CTC 檢測試劑盒的需求，從而推動市場成長。

COVID-19 影響分析

COVID-19 大流行對循環腫瘤細胞市場產生了重大影響。這場大流行造成了全球醫療保健系統的中斷，導致癌症篩檢、診斷和治療的延誤。這反過來又影響了對基於 CTC 的測試和技術的需求。此外，對非必要醫療程序的限制和患者就診醫療機構的減少導致基於 CTC 的檢測的採用率下降。

循環腫瘤細胞市場公司

該市場的主要全球參與者包括 Thermo Fisher Scientific Inc.、QIAGEN、Fluxion Biosciences, Inc.、Greiner Bio One International GmbH、Ikonisys Inc.、BioFluidica、Biolidics Limited、Creativ MicroTech Inc.、Menarini Silicon Biosystems、StemCell Technologies 等。

主要進展

2023 年 9 月，全球領先的液體活體組織切片公司 ANGLE plc 宣布推出其 Portrait (TM) Flex CTC 檢測方法，該公司為腫瘤研究和診斷市場提供創新的循環腫瘤細胞 (CTC) 診斷解決方案。此檢測由 ANGLE 符合 GCP 標準的 Onc-ADaPT (TM) 實驗室提供，並由在 CTC 分析方面擁有 10 多年經驗的專家團隊進行。

2023 年 7 月，液體活體組織切片和單細胞技術先驅 Menarini Silicon Biosystems (MSB) 表示，其新的 CELLSEARCH CTC 實驗室服務可用於檢測腫瘤細胞中 Delta 樣配體 3 (DLL3) 蛋白的表達在血液中循環。此生物標記主要在難以治療的癌症中表現。新的 MSB 實驗室服務為開發進一步的微創測試打開了大門，這些測試在需求未滿足的醫療環境中利用生物標記的預後和預測價值。

2021年5月，ARUP實驗室表示，已與總部位於麻薩諸塞州的TellBio Inc.簽署策略協議，在多項研究應用中使用該開發階段生物技術公司的TellDx循環腫瘤細胞（CTC）技術。

為什麼購買報告？

根據產品類型、技術、應用、樣本、最終用戶和地區可視化全球循環腫瘤細胞市場細分，並了解關鍵商業資產和參與者。

透過分析趨勢和共同開發來識別商業機會。

Excel資料表包含所有細分市場層級的循環腫瘤細胞的大量資料點。

PDF 報告由詳盡的質性訪談和深入研究後的綜合分析組成。

產品映射以 Excel 形式提供，包含所有主要參與者的關鍵產品。

全球循環腫瘤細胞市場報告將提供約 77 個表格、79 個圖表和 187 頁。

2024 年目標受眾

製造商/買家

產業投資者/投資銀行家

研究專業人員

新興公司

Circulating tumor cells (CTCs) are tumor cells that shed from the primary tumor and intravasate into the peripheral blood circulation system responsible for metastasis. Sensitive detection of CTCs from clinical samples can serve as an effective tool in cancer diagnosis and prognosis through liquid biopsy.

Current CTC detection technologies mainly reply on biomarker-mediated platforms including magnetic beads, microfluidic chips or size-sensitive microfiltration which can compromise detection sensitivity due to tumour heterogeneity. A more sensitive, biomarker-independent CTCs isolation technique has been recently developed with the surface-charged superparamagnetic nanoprobe capable of different EMT subpopulation CTC capture from 1 mL clinical blood.

Circulating Tumor Cells Market Drivers and Restraints

Increasing number of cancer cases

The increasing number of cancer cases is one of the significant key factors that help the market to grow during the forecast period. For instance, according to the National Center for Health Statistics. In 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. Cancer incidence increased for prostate cancer by 3% annually from 2014 through 2019 after two decades of decline, translating to an additional 99,000 new cases; otherwise, however, incidence trends were more favourable in men compared to women.

As cancer prevalence rises, there is a growing need for effective cancer diagnostics and monitoring tools along with CTC-based assays and technologies. This presents a significant opportunity for companies operating in the market to develop innovative products and solutions that enable the detection, enumeration, and molecular characterization of CTCs.

Additionally, the growing interest in liquid biopsy approaches further fuels the demand for CTC-based technologies, as they offer a non-invasive method for real-time monitoring of cancer patients.

Furthermore, the circulating tumor cells market is also driven by various other factors like, advancements in CTC detection technologies, increasing demand for rapid cancer diagnosis, development of targeted therapies and others will also help the market to grow during the forecast period.

Market Dynamics: Restraint

Various factors which hamper the market growth during the forecast period some which are Stringent regulatory framework, technical difficulties in CTC detection, cost containment measures, lack of knowledge about advanced CTC technologies, and time-consuming requirements for product launch approvals.

Circulating Tumor Cells Market Segment Analysis

The global circulating tumor cells market is segmented based on product type, technology, application, specimen, end user and region.

The devices segment from the product type segment accounted for approximately 43.5% of the circulating tumor cells market share

The devices from the product type segment accounted for approximately 43.5% and are expected to be dominated during the forecast period. This segment focuses on developing and utilizing devices specifically designed for CTC-related applications. To enhance technical capabilities and facilitate mass production, the market has witnessed the introduction of manufactured glass microchips, which address challenges and improve overall efficiency.

For instance, in June 2020, SCIENION AG and RareCyte Inc. stated that cellenONE proved to be the most appropriate device for accurate single-cell dispensing of low numbers of model circulating tumor cells (CTCs) in oncology applications. RareCyte uses the versatile technology of SCIENIONOs French subsidiary Cellenion for precise and reproducible dosing of a predefined number of targeted CTCs into blood samples.

Circulating Tumor Cells Market Geographical Share

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to factors like the increasing prevalence of cancer in the region coupled with advancements in diagnostic technologies as well as rising awareness among healthcare professionals has contributed to the flourishing CTCs market. Also, robust healthcare infrastructure, coupled with significant investments in research and development, has paved the way for innovative CTC detection and analysis techniques.

For instance, according to the estimates of the 2022, American Cancer Society, Inc., about 236,740 new cases of lung cancer will be diagnosed in the country in 2022. The same source also states that 79,000 new cases of kidney cancer and 13,920 deaths will be reported in 2022 from kidney cancer. The high burden of cancer is expected to boost the demand for CTC detection kits, thereby driving market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic had a significant impact on the circulating tumor cells market. The pandemic caused disruptions in healthcare systems worldwide, leading to delays in cancer screenings, diagnosis, and treatment. This, in turn, affected the demand for CTC-based tests and technologies. Moreover, restrictions on non-essential medical procedures and reduced patient visits to healthcare facilities resulted in a decline in the adoption of CTC-based assays.

Circulating Tumor Cells Market Companies

The major global players in the market include Thermo Fisher Scientific Inc, QIAGEN, Fluxion Biosciences, Inc., Greiner Bio One International GmbH, Ikonisys Inc., BioFluidica, Biolidics Limited, Creativ MicroTech Inc., Menarini Silicon Biosystems, StemCell Technologies among others.

Key Developments

In September 2023, ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumor cell (CTC) diagnostic solutions for the research and diagnostic oncology market, stated the launch of its Portrait™ Flex CTC assay. The assay is provided as a service from ANGLE's Onc-ADaPT™ GCP-compliant laboratories and conducted by an expert team with over 10 years of experience in CTC analysis.

In July 2023, Menarini Silicon Biosystems (MSB), a pioneer in liquid biopsy and single-cell technologies, stated the availability of its new CELLSEARCH CTC lab service to detect the expression of the Delta-Like Ligand 3 (DLL3) protein in tumor cells circulating in the bloodstream. This biomarker is mainly expressed in difficult-to-treat cancers. The new MSB lab service opens the door to the development of further minimally invasive tests that leverage the prognostic and predictive value of biomarkers in medical settings with high unmet needs.

In May 2021, ARUP Laboratories stated that it had signed a strategic agreement with Massachusetts-based TellBio Inc. to use the development-stage biotechnology company's TellDx circulating tumor cells (CTCs) technology in several research applications.

Why Purchase the Report?

To visualize the global circulating tumor cells market segmentation based on product type, technology, application, specimen, end user and region as well as understand key commercial assets and players.

Identify commercial opportunities by analysing trends and co-development.

Excel data sheet with numerous data points of circulating tumor cells market-level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as excel consisting of key products of all the major players.

The global circulating tumor cells market report would provide approximately 77 tables, 79 figures and 187 Pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Technology
3.3. Snippet by Application
3.4. Snippet by Specimen
3.5. Snippet by End User
3.6. Snippet by Region

4. Market Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing number of cancer cases
  - 4.1.1.2. Advancements in CTC detection technologies
- 4.1.2. Restraints
  - 4.1.2.1. Stringent regulatory approvals
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.1.2. Market Attractiveness Index, By Product Type
7.2. Devices*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Kits & Assays
7.4. Consumables

8. By Technology

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 8.1.2. Market Attractiveness Index, By Technology
8.2. CTC Detection and Enrichment Method*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. CTC Direct Detection Method
8.4. CTC Analysis

9. By Application

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.1.2. Market Attractiveness Index, By Application
9.2. Liquid Biopsy*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Research
9.4. Clinical
9.5. Others

10. By Specimen

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
- 10.1.2. Market Attractiveness Index, By Specimen
10.2. Blood*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Bone Marrow
10.4. Others

11. By End User

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.1.2. Market Attractiveness Index, By End User
11.2. Hospitals*
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Clinics
11.4. Diagnostic Centers

12. By Region

12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 12.1.2. Market Attractiveness Index, By Region
12.2. North America
- 12.2.1. Introduction
- 12.2.2. Key Region-Specific Dynamics
- 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
- 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.2.8.1. U.S.
  - 12.2.8.2. Canada
  - 12.2.8.3. Mexico
12.3. Europe
- 12.3.1. Introduction
- 12.3.2. Key Region-Specific Dynamics
- 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
- 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.3.8.1. Germany
  - 12.3.8.2. UK
  - 12.3.8.3. France
  - 12.3.8.4. Italy
  - 12.3.8.5. Spain
  - 12.3.8.6. Rest of Europe
12.4. South America
- 12.4.1. Introduction
- 12.4.2. Key Region-Specific Dynamics
- 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
- 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.4.8.1. Brazil
  - 12.4.8.2. Argentina
  - 12.4.8.3. Rest of South America
12.5. Asia-Pacific
- 12.5.1. Introduction
- 12.5.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
- 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.5.7.1. China
  - 12.5.7.2. India
  - 12.5.7.3. Japan
  - 12.5.7.4. Australia
  - 12.5.7.5. Rest of Asia-Pacific
12.6. Middle East and Africa
- 12.6.1. Introduction
- 12.6.2. Key Region-Specific Dynamics
- 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
- 12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

13. Competitive Landscape

13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis

14. Company Profiles

14.1. Thermo Fisher Scientific Inc *
- 14.1.1. Company Overview
- 14.1.2. Product Portfolio and Description
- 14.1.3. Financial Overview
- 14.1.4. Key Developments
14.2. QIAGEN
14.3. Fluxion Biosciences, Inc
14.4. Greiner Bio One International GmbH
14.5. Ikonisys Inc
14.6. BioFluidica
14.7. Biolidics Limited
14.8. Creativ MicroTech Inc
14.9. Menarini Silicon Biosystems
14.10. StemCell Technologies (LIST NOT EXHAUSTIVE)